Georgiamune
PrivateLast Round
Series B
Sep 18, 2026
Est. Valuation
$389M
Total Funding Raised
$172.19M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Georgiamune operates in Healthcare & Life Sciences and is based in Gaithersburg, Maryland. Its latest recorded funding round was a Series B round in September 2026.
Georgiamune is a biotechnology company that develops immunotherapies aimed at reprogramming immune signaling pathways to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Georgiamune Comparables
Compare Georgiamune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immune-Onc Therapeutics | 85% | |
| iOmx Therapeutics | 84% | |
| OncoC4, Inc. | 84% |
For institutional investors. Book with your work email.
Georgiamune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 18, 2026 | ||||
| Series B | Jul 16, 2026 | ||||
| Series A | Aug 9, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Georgiamune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Prevail Strategies | Series B |
| Parker Institute for Cancer Immunotherapy | Series A |
| Catalio Capital Management | Series B, Series A |
| General Catalyst | Series B, Series A |
| Mubadala Capital | Series B, Series A |
| Alexandria Venture Investments | Series B, Series A |
| CJNV BioVenture | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 18, 2026
$93M round led by Mubadala Capital and Prevail Strategies.
- Jul 26, 2026
Monthly visitors increased 139% MoM, reaching 2.6K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- sells_assets_toOct 22, 2026
Georgiamune Inc. sells its preclinical solid tumor cancer drug to Menarini, a family-owned Italian pharma, for up to $1.1B in Italy on Oct 22nd '26.
- receives_financingOct 22, 2026
Georgiamune Inc. is to receive $45M in upfront and near-term payments from the Menarini Group and Stemline under an exclusive worldwide GIM-621 license agreement, with total potential deal value of up to $1.1 billion plus royalties, on Oct 22nd '26.
- licenses_technologyOct 22, 2026
Georgiamune Inc. grants Menarini's Stemline Therapeutics an exclusive worldwide license to develop, manufacture, and commercialize GIM-621, a preclinical-stage oral immunotherapy, on Oct 22nd '26 in Italy and Maryland.
- licenses_technologyOct 22, 2026
On Oct 22nd '26, Georgiamune Inc. grants Stemline exclusive worldwide rights to develop and commercialize GIM-621 for an upfront payment of $45 million and up to $1.1 billion.
- receives_financingSep 17, 2026
Georgiamune Inc. receives $93M in Series B financing in Sep '26 to advance its cancer and autoimmune disease programs.
For institutional investors. Book with your work email.
Georgiamune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Georgiamune's valuation, stock price, and market status.
Is Georgiamune a public or private company?
Georgiamune is a private company.
What is the current stock price of Georgiamune?
Georgiamune is a private company, so its shares have no public market price. Caplight tracks Georgiamune's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Georgiamune worth (valuation)?
Georgiamune's valuation is estimated at $389.0M based on funding round data.
Can I buy Georgiamune stock?
Georgiamune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Georgiamune's last funding round?
Georgiamune's most recent funding round was Series B on September 18, 2026.
Who are the main investors in Georgiamune?
Key investors in Georgiamune include Prevail Strategies, Parker Institute for Cancer Immunotherapy, General Catalyst, Mubadala Capital.
Will Georgiamune IPO soon?
No public IPO plans have been announced for Georgiamune.
How can I track Georgiamune secondary market activity?
Caplight tracks bids, offers, and trades in Georgiamune's shares on secondary markets.